stockportfolio.pro
Eli Lilly and Company (LLY)
Healthcare · Drug Manufacturers - General · NYSE
Eli Lilly and Company revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.22B | $19.97B | $21.49B | $22.32B | $24.54B | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B |
| Gross profit | $15.51B | $15.53B | $16.81B | $17.60B | $19.06B | $21.01B | $21.91B | $27.04B | $36.62B | $54.13B |
| Net income | $2.74B | $-204.10M | $3.23B | $8.32B | $6.19B | $5.58B | $6.24B | $5.24B | $10.59B | $20.64B |
| Net margin | 12.9% | -1.0% | 15.0% | 37.3% | 25.2% | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
Source: Eli Lilly and Company SEC filings (10-K). 19 years of history available in the interactive view.
Explore 19 years of Eli Lilly and Company financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LLY in your portfolio →
Eli Lilly and Company financial history by metric
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company — frequently asked questions
What is Eli Lilly and Company's revenue?
Eli Lilly and Company (LLY) reported revenue of $65.18B for fiscal year 2025, up 44.7% from the prior year, according to its SEC filings.
Is Eli Lilly and Company profitable?
Yes. LLY earned net income of $20.64B in fiscal 2025, a net margin of 31.7%.
What is LLY's P/E ratio?
Eli Lilly and Company trades at a price-to-earnings ratio of about 40.7 based on the latest data in our nightly-refreshed cache.
How fast is Eli Lilly and Company growing?
LLY's revenue grew at roughly 21.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Eli Lilly and Company have?
As of fiscal year 2025, LLY carried roughly $42.50B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Eli Lilly and Company's gross margin?
LLY's gross margin was 83.0% in fiscal 2025 — gross profit of $54.13B on revenue of $65.18B.
What is Eli Lilly and Company's market cap?
Eli Lilly and Company (LLY) has a market capitalization of about $1.02T, based on the latest data in our nightly-refreshed cache.
When does Eli Lilly and Company's fiscal year end?
LLY's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Eli Lilly and Company's official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.